证券日报网讯9月9日晚间，畅联股份（603648）发布公告称，董事会于2025年9月9日收到公司独立董事 李征宇先生的书面辞职报告，因其连续担任公司独立董事职务即将届满6年，根据《上市公司独立董事 管理办法》的规定，李征宇先生辞去公司独立董事及董事会战略委员会委员、审计委员会委员、薪酬与 考核委员会委员、提名委员会委员职务。辞职后，李征宇先生将不再担任公司任何职务。 ...

证券代码：603648 证券简称：畅联股份 公告编号：2025-024 上海畅联国际物流股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海畅联国际物流股份有限公司(以下简称"公司")董事会于 2025 年 9 月 9 日收到公司独立董事李征宇先生的书面辞职报告，因其连续担任公司独立董 事职务即将届满 6 年，根据《上市公司独立董事管理办法》的规定，李征宇 先生辞去公司独立董事及董事会战略委员会委员、审计委员会委员、薪酬与 考核委员会委员、提名委员会委员职务。辞职后，李征宇先生将不再担任公 司任何职务。截至本公告披露日，李征宇先生未持有公司股份，不存在应当 履行而未履行的承诺事项。 | 是否继续 | 是否存在 | 原定任 | 在上市公 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 未履行完 | 姓名 | 离任职务 | 离任时间 | 期到期 | 离任原因 | 司及其控 | 毕的公开 | | 日 | 股子公司 | 承诺 | ...

Core Viewpoint - Changlian Co., Ltd. (603648) reported disappointing financial results for the first half of 2025, with significant declines in revenue and net profit compared to the previous year [1] Financial Performance Summary - Total revenue for the first half of 2025 was 739 million yuan, a decrease of 10.78% year-on-year [1] - Net profit attributable to shareholders was 68.31 million yuan, down 14.62% year-on-year [1] - In Q2 2025, total revenue was 391 million yuan, a decline of 3.64% year-on-year [1] - Q2 2025 net profit attributable to shareholders was 36.62 million yuan, a decrease of 7.29% year-on-year [1] Key Financial Metrics - Gross margin was 20.51%, an increase of 2.43% year-on-year [1] - Net margin was 9.76%, a decrease of 3.89% year-on-year [1] - Total expenses (selling, administrative, and financial) amounted to 60.57 million yuan, representing 8.19% of revenue, an increase of 11.0% year-on-year [1] - Earnings per share (EPS) was 0.19 yuan, down 13.64% year-on-year [1] - Operating cash flow per share was 0.28 yuan, a decrease of 27.24% year-on-year [1] Balance Sheet Insights - Cash and cash equivalents increased to 234 million yuan, up 4.14% year-on-year [1] - Accounts receivable stood at 241 million yuan, a slight decrease of 1.98% year-on-year [1] - Interest-bearing debt rose to 142 million yuan, an increase of 53.59% year-on-year [1] Return on Investment Analysis - The company's return on invested capital (ROIC) for the previous year was 6.7%, indicating generally average capital returns [1] - Historical median ROIC since listing is 8.64%, suggesting relatively good investment returns [1] - The lowest recorded ROIC was 6.36% in 2020, reflecting average investment returns historically [1]

Core Viewpoint - Shanghai Shine-Link International Logistics Co., Ltd. reported a decline in key financial metrics for the first half of 2025, indicating challenges in revenue generation and profitability compared to the previous year [1][2]. Financial Performance - The company's operating revenue for the first half of 2025 was approximately ¥739.40 million, a decrease of 10.78% from ¥828.75 million in the same period last year [3][9]. - Total profit for the period was about ¥86.37 million, down 14.17% from ¥100.62 million year-on-year [3][9]. - Net profit attributable to shareholders was approximately ¥68.31 million, reflecting a 14.62% decline from ¥80.01 million in the previous year [3][9]. - The net cash flow from operating activities was ¥100.32 million, a significant drop of 27.24% compared to ¥137.88 million in the same period last year [3][9]. Key Financial Indicators - Basic earnings per share decreased to ¥0.1885, down 14.63% from ¥0.2208 [3][9]. - The weighted average return on net assets was 3.63%, a decrease of 0.62 percentage points from the previous year [3][9]. - The company's net assets attributable to shareholders at the end of the reporting period were approximately ¥1.81 billion, down 2.21% from ¥1.85 billion at the end of the previous year [3][9]. Business Overview - The company focuses on providing lean supply chain management services for international multinational enterprises, utilizing advanced information technology and IoT solutions [4][5]. - Key sectors served include high-tech electronics, medical devices, machinery components, imported food, and apparel [4][5]. Competitive Advantages - The company emphasizes a comprehensive service model that integrates various supply chain functions, enhancing operational efficiency and reducing costs for clients [4][5]. - A strong emphasis on information technology has led to the development of a "smart logistics" model, improving service delivery and customer satisfaction [4][5]. - The company has established long-term strategic partnerships with several Fortune 500 companies, ensuring a stable and high-quality customer base [4][5]. Operational Developments - The company has been expanding its national logistics network, with significant operations in major cities across China and a recent establishment of a wholly-owned subsidiary in Vietnam [6][7]. - Ongoing construction of logistics bases in Zhengzhou and Kunming is expected to enhance operational capacity and service delivery [7][8]. Recognition and Awards - The company has received multiple awards and recognitions for its contributions to the logistics industry, including being named a key enterprise in medical device logistics [6][8].

Core Viewpoint - Shanghai Changlian International Logistics Co., Ltd. reported a decline in key financial metrics for the first half of 2025, indicating challenges in revenue generation and profitability compared to the previous year [1]. Financial Performance - Total assets decreased by 2.87% to CNY 2,495,718,795.86 from CNY 2,569,470,141.73 at the end of the previous year [1]. - Net assets attributable to shareholders fell by 2.21% to CNY 1,807,315,792.06 from CNY 1,848,070,111.84 [1]. - Operating revenue dropped by 10.78% to CNY 739,395,671.52 compared to CNY 828,748,952.24 in the same period last year [1]. - Total profit decreased by 14.17% to CNY 86,365,472.82 from CNY 100,623,552.22 [1]. - Net profit attributable to shareholders decreased by 14.62% to CNY 68,309,664.76 from CNY 80,010,974.38 [1]. - Net cash flow from operating activities declined by 27.24% to CNY 100,321,269.74 from CNY 137,882,956.51 [1]. - The weighted average return on net assets decreased by 0.62 percentage points to 3.63% from 4.25% [1]. - Basic and diluted earnings per share both fell by 14.63% to CNY 0.1885 from CNY 0.2208 [1]. Shareholder Information - The largest shareholder, Shanghai Pudong New Area State-owned Assets Supervision and Administration Commission, holds 25.30% of the shares [2]. - Other significant shareholders include Shanghai Yidian (Group) Co., Ltd. with 13.70% and Shanghai Waigaoqiao Free Trade Zone United Development Co., Ltd. with 10.50% [2]. - The total number of shareholders at the end of the reporting period was 21,431 [2].

证券代码：603648 证券简称：畅联股份 公告编号：2025-021 上海畅联国际物流股份有限公司 第四届董事会第十二次会议决议公告 具体内容详见同日公司在上海证券交易所网站（www.sse.com.cn）披露的 《上海畅联国际物流股份有限公司 2025 年半年度报告》及《上海畅联国际物流股 份有限公司 2025 年半年度报告摘要》。 同意公司出资人民币 3,000 万元与关联方上海外高桥生物医药产业发展有限 公司共同设立上海畅联百福医药有限公司（暂定名，以最终工商核准为准），公司 占上海畅联百福医药有限公司股权比例 60%。 上海畅联国际物流股份有限公司（以下简称"公司"）第四届董事会第十二 次会议于 2025 年 8 月 27 日在公司会议室以现场结合通讯表决方式召开。会议通 知及会议材料于 2025 年 8 月 11 日以电子邮件、电话等形式发出。本次会议由董 事长尹强先生主持，应出席董事 11 名，实际出席董事 11 名，其中亲自出席会议 的董事 10 名，副董事长俞勇先生因个人原因委托董事长尹强先生代为出席。会议 参与表决人数及召集、召开程序符合《公司法》和《公司章程》的有关规定，所 作决议合法有 ...

Core Viewpoint - Changlian Co., Ltd. (603648.SH) reported a decline in revenue and net profit for the first half of 2025, indicating challenges in its operational performance compared to peers in the industry [1][3]. Financial Performance - The company's total revenue for the first half of 2025 was 739 million yuan, ranking 27th among disclosed peers, a decrease of 89.35 million yuan or 10.78% year-on-year [1]. - The net profit attributable to shareholders was 68.31 million yuan, ranking 19th among peers, down by 11.70 million yuan or 14.62% year-on-year [1]. - Operating cash flow was 100 million yuan, ranking 18th among peers, a decrease of 37.56 million yuan or 27.24% year-on-year [1]. Key Ratios - The latest debt-to-asset ratio was 26.94%, ranking 4th among peers, an increase of 4.98 percentage points from the previous quarter and 7.70 percentage points from the same period last year [3]. - The gross profit margin was 20.51%, ranking 8th among peers, an increase of 0.25 percentage points from the previous quarter and 0.49 percentage points year-on-year [3]. - Return on equity (ROE) was 3.78%, ranking 15th among peers, a decrease of 0.38 percentage points year-on-year [3]. Earnings Per Share and Turnover - The diluted earnings per share were 0.19 yuan, ranking 18th among peers, a decrease of 0.03 yuan or 13.95% year-on-year [3]. - The total asset turnover ratio was 0.29 times, ranking 29th among peers, a decrease of 0.05 times year-on-year [3]. - The inventory turnover ratio was 31.06 times, ranking 16th among peers, an increase of 19.11 times or 159.80% year-on-year [3]. Shareholder Structure - The number of shareholders was 21,400, with the top ten shareholders holding 211 million shares, accounting for 58.32% of the total share capital [3]. - The largest shareholder is the State-owned Assets Supervision and Administration Commission of Pudong New Area, holding 25.30% [3].

Core Viewpoint - Shanghai Changlian International Logistics Co., Ltd. plans to establish a joint venture, Shanghai Changlian Baifu Pharmaceutical Co., Ltd., with Shanghai Waigaoqiao Biomedical Industry Development Co., Ltd. The registered capital of the new company will be RMB 50 million, with Changlian contributing RMB 30 million for a 60% stake, while the biomedical company will contribute RMB 20 million for a 40% stake. This project is not expected to have a significant short-term impact on the company's revenue, profit, or cash flow [3][4][5]. Company Overview - The new company, Shanghai Changlian Baifu Pharmaceutical Co., Ltd., will focus on supply chain management services in the pharmaceutical sector, leveraging Changlian's existing advantages in the medical device sector [5][6]. - The establishment of the new company aligns with the company's strategic goal of expanding into the pharmaceutical sector, enhancing its overall competitiveness [11]. Investment and Transaction Details - The joint investment constitutes a related party transaction, with the investment amount of RMB 30 million representing 1.62% of the company's net assets as of 2024 [6][9]. - The transaction has been approved by the company's independent directors, audit committee, board of directors, and supervisory board, and does not require shareholder approval [4][15][30]. Business Synergy and Market Context - The new company aims to create a standardized logistics warehouse for pharmaceuticals, supporting the development of the biomedical industry in the Shanghai Free Trade Zone [5][10]. - The establishment of the new company is expected to enhance the regional investment ecosystem and foster the development of pharmaceutical research and manufacturing projects [5][9]. Governance Structure - The new company will have a governance structure consisting of a shareholders' meeting, a board of directors, and a general manager, with the board comprising five members [11][12].

Group 1 - The company announced that its fourth board meeting approved multiple proposals, including the review of the general manager's work report for the first half of 2025 [2]

Group 1 - The company Changlian Co., Ltd. announced on the evening of August 28 that its fourth supervisory board's tenth meeting approved the proposal regarding the company's semi-annual report for the first half of 2025 and its summary [2]